ACE-031 and RAD-140 Interaction

Monitor
Mechanism-based 46% confidence

ACE-031 and RAD-140 have an interaction requiring monitoring for interaction with 46% confidence. Both ACE-031 and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Half-life: 12-15 days Typical dose: 0.5-3 mg/kg IV every 2 weeks (clinical research doses only) growth hormone, anabolic
actriibmyostatintgf beta androgenicanticoagulantblood pressure raisinghpta suppressive
View full profile

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Half-life: ~60 hours Typical dose: 10-20 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskcrosses bbb
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (ACE-031, RAD-140). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds raise blood pressure (ACE-031, RAD-140). Monitor BP daily and consider cardiovascular support.
2x 2 HPTA-suppressive compounds (ACE-031, RAD-140). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (ACE-031, RAD-140). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take ACE-031 with RAD-140?

Yes, but with caution. Both ACE-031 and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and RAD-140 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, hpta suppressive, lipid disrupting. Monitor accordingly.

What are the interactions between ACE-031 and RAD-140?

Both ACE-031 and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and RAD-140?

ACE-031 has a half-life of 12-15 days and RAD-140 has a half-life of ~60 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: ACE-031 vs RAD-140

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.